Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients
- PMID: 20191492
- DOI: 10.1002/acr.20015
Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients
Abstract
Objective: To investigate the long-term outcome and prognostic factors of juvenile dermatomyositis (DM) through a multinational, multicenter study.
Methods: Patients consisted of inception cohorts seen between 1980 and 2004 in 27 centers in Europe and Latin America. Predictor variables were sex, continent, ethnicity, onset year, onset age, onset type, onset manifestations, course type, disease duration, and active disease duration. Outcomes were muscle strength/endurance, continued disease activity, cumulative damage, muscle damage, cutaneous damage, calcinosis, lipodystrophy, physical function, and health-related quality of life (HRQOL).
Results: A total of 490 patients with a mean disease duration of 7.7 years were included. At the cross-sectional visit, 41.2-52.8% of patients, depending on the instrument used, had reduced muscle strength/endurance, but less than 10% had severe impairment. Persistently active disease was recorded in 41.2-60.5% of the patients, depending on the activity measure used. Sixty-nine percent of the patients had cumulative damage. The frequency of calcinosis and lipodystrophy was 23.6% and 9.7%, respectively. A total of 40.7% of the patients had decreased functional ability, but only 6.5% had major impairment. Only a small fraction had decreased HRQOL. A chronic course, either polycyclic or continuous, consistently predicted a poorer outcome. Mortality rate was 3.1%.
Conclusion: This study confirms the marked improvement in functional outcome of juvenile DM when compared with earlier literature. However, many patients had continued disease activity and cumulative damage at followup. A chronic course was the strongest predictor of poor prognosis. These findings highlight the need for treatment strategies that enable a better control of disease activity over time and the reduction of nonreversible damage.
Similar articles
-
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.Arthritis Rheum. 2000 Mar;43(3):541-9. doi: 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T. Arthritis Rheum. 2000. PMID: 10728746
-
Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.Arthritis Rheum. 2009 Apr 15;61(4):509-17. doi: 10.1002/art.24343. Arthritis Rheum. 2009. PMID: 19333974
-
Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study.Scand J Rheumatol. 2012 Feb;41(1):50-8. doi: 10.3109/03009742.2011.608376. Epub 2011 Nov 1. Scand J Rheumatol. 2012. PMID: 22044089
-
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.Rheumatology (Oxford). 2003 Dec;42(12):1452-9. doi: 10.1093/rheumatology/keg403. Epub 2003 Jun 27. Rheumatology (Oxford). 2003. PMID: 12832713 Review.
-
Juvenile dermatomyositis: extramuscular manifestations and their management.Curr Opin Rheumatol. 2009 Nov;21(6):575-80. doi: 10.1097/BOR.0b013e328331927e. Curr Opin Rheumatol. 2009. PMID: 19730375 Review.
Cited by
-
Inpatient burden of juvenile dermatomyositis among children in the United States.Pediatr Rheumatol Online J. 2018 Nov 13;16(1):70. doi: 10.1186/s12969-018-0286-1. Pediatr Rheumatol Online J. 2018. PMID: 30424778 Free PMC article.
-
Multispecialty approach for improving outcomes in juvenile dermatomyositis.J Multidiscip Healthc. 2019 May 29;12:387-394. doi: 10.2147/JMDH.S171095. eCollection 2019. J Multidiscip Healthc. 2019. PMID: 31213823 Free PMC article. Review.
-
Coordinated immune dysregulation in juvenile dermatomyositis revealed by single-cell genomics.JCI Insight. 2024 May 14;9(12):e176963. doi: 10.1172/jci.insight.176963. JCI Insight. 2024. PMID: 38743491 Free PMC article.
-
Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.Paediatr Drugs. 2025 Jan;27(1):57-72. doi: 10.1007/s40272-024-00658-2. Epub 2024 Oct 19. Paediatr Drugs. 2025. PMID: 39425894 Free PMC article. Review.
-
Consensus-based recommendations for the management of juvenile dermatomyositis.Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11. Ann Rheum Dis. 2017. PMID: 27515057 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources